首页 | 本学科首页   官方微博 | 高级检索  
   检索      

长效缓释微球制剂生产技术的发展现状
引用本文:徐明新,陶 颖,陈园园,Jebun Nessa Dian,袁伟恩.长效缓释微球制剂生产技术的发展现状[J].现代生物医学进展,2017,17(19):3772-3775.
作者姓名:徐明新  陶 颖  陈园园  Jebun Nessa Dian  袁伟恩
作者单位:上海交通大学药学院 上海 200240
基金项目:国家自然科学基金项目(81373366);上海市自然基金项目(15ZR1432500);上海交通大学医工交叉项目(YG2013MS52,YG2013MS62,YG2014QN06)
摘    要:长效缓释微球是将药物溶解或分散在高分子骨架材料中的微米级别的药物释放载体,这种新剂型可以显著降低给药频率,同时大分子材料的包裹可以提高药物的稳定性,降低药物的毒副作用,目前广泛应用在蛋白多肽等药物。已有一些用于治疗糖尿病、精神病、子宫内膜异位等疾病的长效缓释微球制剂被批准上市。然而,因为微球的制备工艺繁杂、质量控制困难,至今只在少数产品上应用,现在越来越多的口服难吸收的生物药物开始产品化,长效缓释微球在提高患者依从性方面备受瞩目。本综述对目前典型的微球制备技术做出分析和评判,以期对完善微球制备工艺有所帮助。

关 键 词:微球  工业化  膜乳化
收稿时间:2016/12/9 0:00:00
修稿时间:2016/12/24 0:00:00

Advanced Studies in the Preparation Techniques of Sustained-release Microsphere
Abstract:ABSTRACT: Long-acting microspheres, as a kind of micron level drug carrier, are made from drug dissolving or dispersing in poly- mer materials. This new dosage form can significantly reduce dosing frequency, improve the stability and reduce the side effects of drugs with macromolecular material package. Nowadays, microspheres become widely used in protein polypeptide drugs. Some sustained-re- lease microsphere dosage forms have been launched to the market for diabetes, mental disease and endometriosis. However, only a few microsphere products due to their complicated manufacture processes and difficulties in quality control. As more and more orally non-ab- sorbable biologic medicines are coming to commercialization, microspheres will become more favorable in terms of improving patient compliance. In article the typical microspheres are reviewed with the purpose of helping scientists and students in pharmaceutical sci- ences to improve the art of microsphere formulation with the analysis and critiques we offered.
Keywords:Microsphere  Industry  Membrane emulsification
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号